display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
locally advanced NSCLC - (neo)adjuvant (NA)
locally advanced NSCLC - (neo)adjuvant (NA)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC CheckMate 816

Study type: